Stocks of Clever Leaves Holdings Inc. (NASDAQ:CLVRW) are soaring as of late Friday following reports indicating the U.S. House Rules Committee has scheduled a Monday afternoon meeting to prepare the MORE Act, a federal marijuana legalization bill, for floor action. Clever Leaves is a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids.

Shares of several other cannabis firms, including Aurora Cannabis Inc (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Cronos Group Inc (NASDAQ:CRON), Sundial Growers Inc (NASDAQ:SNDL), and Tilray Inc (NASDAQ:TLRY), are all trending higher

“Yesterday’s call brought not just impressive overall earnings figures but also the reaffirmation of Clever Leaves’ 2022 outlook. The quarter saw revenue hit $4.2 million, a gain of roughly 25%. Revenue from cannabinoids rose 11% to $1.1M, while for the non-cannabinoid category it spiked by 31% and reached $3.1 million. Revenues were driven by increased distributor demand and expanding sales activity,” reported investorplace.com

The Marijuana Justice Coalition (MJC), a broad coalition of national advocacy organizations convened by the Drug Policy Alliance, including the American Civil Liberties Union and Human Rights Watch, sent a letter to House Speaker Nancy Pelosi (D-CA) and House Majority Leader Steny Hoyer (D-MD) earlier this month, calling for a floor vote on the bill.

The MORE Act repeals the long-standing federal prohibition of marijuana by removing it from the Controlled Substances Act, that way ending the state/federal conflict over cannabis policies and providing state governments with greater authority to regulate marijuana-related activities, including retail sales.

“The MORE Act de-schedules cannabis and provides money for communities that were impacted by the War on Drugs, it is similar to the CAO Act, but we expect the CAO to go further and establish federal agencies’ jurisdictions because cannabis has different properties medical, therapeutic… and that speaks to the role of FDA, which controls anything having to do with medicine in the country,” said Steven Hawkins, president, and CEO of the US Cannabis Council, in an exclusive interview with Benzinga. “If MORE passes the cannabis sector is free to engage in business as usual.”